Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Growth | Market Cap | Revenue | EBITDA | Earnings | EPS | Rev. Y/Y | Rev. 5Y | Earn. Y/Y | Earn. 5Y | Earnings Date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SLNO | SOLENO THERAPEUTICS INC | $1.73B | $190.41M | $28.99M | $20.48M | $0.40 | N/A | N/A | N/A | N/A | |||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $43.88B | $3.71B | $631.44M | $313.75M | $2.39 | 65.19% | 49.77% | N/A | N/A | |||
| ZVRA | ZEVRA THERAPEUTICS INC | $547.19M | $106.47M | $99.31M | $83.23M | $1.40 | 350.91% | 51.62% | N/A | N/A | 2026-05-19 | ||
| ADMA | ADMA BIOLOGICS INC | $2.15B | $510.17M | $197.86M | $146.93M | $0.62 | 19.63% | 64.60% | -27.06% | N/A | |||
| CORT | CORCEPT THERAPEUTICS INC | $4.29B | $761.41M | $45.21M | $98.17M | $0.95 | 12.79% | 16.56% | -29.63% | 0.64% | 2026-05-06 | ||
| ABEO | ABEONA THERAPEUTICS INC | $255.58M | $5.82M | $78.59M | $71.18M | $1.34 | N/A | -10.26% | N/A | N/A | 2026-05-07 | ||
| HALO | HALOZYME THERAPEUTICS INC | $7.63B | $1.40B | $573.05M | $316.89M | $2.64 | 37.55% | 39.16% | -24.57% | 22.68% | 2026-05-12 | ||
| KRYS | KRYSTAL BIOTECH INC | $7.55B | $389.13M | $196.02M | $204.83M | $7.08 | 33.94% | N/A | 126.92% | N/A | 2026-05-11 | ||
| NAGE | NIAGEN BIOSCIENCE INC | $353.15M | $129.42M | $19.64M | $17.38M | $0.22 | 29.95% | 16.91% | 100.00% | N/A | 2026-05-13 | ||
| RPRX | ROYALTY PHARMA PLC | $27.67B | $2.38B | $1.08B | $770.95M | $1.79 | 5.06% | 2.30% | -6.77% | 6.28% | 2026-05-07 | ||
| VCEL | VERICEL CORP | $1.63B | $276.26M | $34.90M | $16.52M | $0.33 | 16.45% | 17.34% | 57.14% | 40.63% | |||
| APLS | APELLIS PHARMACEUTICALS INC | $5.14B | $1.00B | $70.00M | $22.39M | $0.18 | 28.46% | 31.98% | N/A | N/A | 2026-04-30 | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.62B | $868.45M | $255.05M | $158.69M | $2.76 | 21.51% | 40.30% | 7.81% | N/A | 2026-05-05 | ||
| MNKD | MANNKIND CORP | $754.85M | $348.97M | $52.93M | $5.86M | $0.02 | 22.23% | 39.89% | -80.00% | N/A | |||
| TECH | BIO-TECHNE CORP | $8.18B | $1.22B | $226.43M | $81.10M | $0.52 | 1.64% | 8.76% | -48.00% | -14.59% | 2026-05-06 | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10.86B | $3.22B | $572.94M | $348.90M | $1.82 | 12.87% | 11.60% | -19.11% | -17.35% | |||
| EXEL | EXELIXIS INC | $11.14B | $2.32B | $994.49M | $782.57M | $2.88 | 6.98% | 18.63% | 60.00% | 51.57% | 2026-05-06 | ||
| VCYT | VERACYTE INC | $2.56B | $517.15M | $92.61M | $66.35M | $0.84 | 16.01% | 34.50% | 162.50% | N/A | 2026-05-12 | ||
| XOMA | XOMA ROYALTY CORP | $373.48M | $52.15M | $34.69M | $18.52M | $1.53 | 83.06% | 12.16% | N/A | 13.29% | 2026-05-12 | ||
| REGN | REGENERON PHARMACEUTICALS INC | $81.68B | $14.34B | $5.82B | $4.50B | $43.07 | 0.99% | 11.04% | 5.31% | 5.70% | 2026-04-30 | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $3.02B | $588.99M | $321.68M | $214.33M | $1.75 | 19.78% | 37.68% | 26.81% | 19.44% | |||
| VRTX | VERTEX PHARMACEUTICALS INC | $113.44B | $12.00B | $4.87B | $3.95B | $15.46 | 8.90% | 14.10% | N/A | 8.17% | |||
| LGND | LIGAND PHARMACEUTICALS INC | $3.98B | $268.09M | $199.39M | $124.45M | $6.44 | 60.40% | 10.39% | N/A | N/A | 2026-05-13 | ||
| UTHR | UNITED THERAPEUTICS CORP | $25.99B | $3.18B | $1.82B | $1.33B | $30.13 | 10.61% | 16.50% | 13.96% | 20.93% | 2026-05-06 | ||
| INCY | INCYTE CORP | $18.73B | $5.14B | $1.76B | $1.29B | $6.59 | 21.22% | 14.03% | 4,018.75% | N/A | 2026-05-05 | ||
| CRMD | CORMEDIX INC | $536.75M | $311.71M | $167.35M | $163.06M | $2.25 | 617.03% | 319.75% | N/A | N/A | |||
| MDXG | MIMEDX GROUP INC | $586.84M | $418.63M | $79.47M | $48.58M | $0.33 | 19.99% | 11.02% | 13.79% | N/A | 2026-05-05 |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.